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There is increasing evidence showing that apoptosis plays a role in the development of the autoimmune thyroid
diseases—Hashimoto’s (lymphocytic) thyroiditis (HT) and Graves’ disease (GD). The immune pathogenesis of HT
and GD is not yet fully understood, but evidence points toward several steps. A defect in CD4+CD25+ T regulatory
cells breaks the immunological tolerance of the host and induces an abnormal production of cytokines, which
facilitates the initiation of apoptosis. Though apoptosis appears to play a role in the pathogenesis of both HT and
GD, the mechanisms that mediate these processes appear different. The induction of apoptosis in HT results in the
destruction of thyrocytes, while apoptosis in the GD leads to damage of thyroid-infiltrating lymphocytes. The
differences in the apoptotic mechanisms produce two very different forms of thyroid autoimmune responses,
eventually developing into HT and GD, respectively.
Introduction
Autoimmune thyroid disease (AITD) is the most com-mon organ-specific autoimmune disorder. The etiology
of AITD is still unclear, but the susceptibility to it is deter-
mined by a combination of genetic and environmental factors.
The pathogenesis of AITD is known to be associated with
autoimmune processes against various constituents of thyroid
tissues, including cell membranes, receptors, and enzymes.
AITD affects 1–2% of the population, with a 5- to 10-fold in-
crease among women. AITD encompasses two entities: auto-
immune thyroiditis and autoimmune hyperthyroidism. The
former is represented by Hashimoto’s (lymphocytic) thyroid-
itis (HT) and the latter by Graves’ disease (GD).
No unique immune response to thyroid autoantigens has
been identified that is absolutely correlated with the expres-
sion of clinical AITD (1). The triggering event for AITD is not
known, but the pathogenesis of AITD appears to be multi-
factorial. Genetic background and environmental and endo-
genous factors are thought to play important roles in
determining the activation threshold of immune cells or the
efficacy of the immunoregulatory pathways. However, the
procedures responsible for this process are just being clarified.
Apoptosis—or programmed cell death—is an evolution-
arily preserved mechanism of the self-elimination of damaged
cells. It is important throughout the life of an organism,
playing a role in every process from development to ag-
ing. The apoptotic cascade can be triggered either through a
death receptor–mediated pathway or through mitochondrial-
mediated changes. During the past few years, increasing evi-
dence has suggested that receptor-mediated apoptosis plays
a key role in the process of AITD development, the common
feature of which is the survival of specific, unchecked self-
reactive lymphocytes against the thyroid (2–4). While several
of our prior reviews have focused on the regulation of apo-
ptosis in the thyroid, we are focusing this discussion on the
role of apoptosis in immune pathogenesis of these diseases.
The homeostasis of the self-reactive lymphocytes is decided
by the balance between antiapoptotic and proapoptotic mol-
ecules. The loss of this balance may lead to the self-immune
system’s attack on the thyroid, during which organ-specific
lymphocytes can convey death signals to thyroid follicular
cells. This initiates damage to the thyroid, leading to hypo-
thyroidism in HT or to hyperthyroidism in GD. In this review,
we will discuss the role of apoptosis in the pathogenesis of HT
and GD.
Hashimoto’s Thyroiditis
HT is characterized by inflammatory cell infiltration of the
thyroid parenchyma, causing a dense accumulation of lym-
phocytes, plasma cells, and macrophages with germinal cen-
ter formation and thyroid enlargement (5). The central feature
of HT is the presence of autoantibodies to thyroglobulin and
to thyroid peroxidase. The etiology of HT is not known, but it
is believed to involve an interplay among genetic, environ-
mental, and endogenous factors. The relative contribution
of each is not clearly defined and may vary from patient to
patient.
There are several steps hypothesized to play a role in the
immune pathogenesis of HT. Initially, the immune system
in an individual susceptible to HT is altered by changes in
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environmental factors and=or endogenous elements. Such
alterations in the immune system appear to result in defects
in the Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4),
CD4þCD25þ T regulatory cells (Treg cells) (6–8), which nor-
mally represent an important mechanism for the maintenance
of self-tolerance. Supporting this concept, studies have shown
that removal of CD4þCD25þ Treg cells from mice that do not
develop autoimmunity can result in autoimmune thyroiditis
(6). Furthermore, adoptive transfer of Treg cells is able to
prevent experimental autoimmune thyroiditis (7–9). The rea-
son that there are fewer and=or dysfunctional Treg cells in
autoimmune pathogenesis remains unclear. However, in sev-
eral autoimmune disease models, a mutation of the forkhead
box protein P3 (Foxp3) gene, which is a characteristic and
functional marker of Treg cells, has been observed (10). A
specific genetic defect may also be responsible for causing an
autoimmune response by inducing autoreactive T cells to
break self-tolerance. This type of genetic defect has also been
reported to be associated with a decreased number of Treg
cells (11). Nevertheless, even in normal hosts, the depletion
of Treg cells can result in defects in the immune surveillance
system, leading to an ‘‘unchecked’’ status with a decrease or
defect in the inhibitory functions of CD4þ and CD8þ T cells
(6,12,13). In such a situation, the host loses immunological tol-
erance and eventually develops autoimmune diseases (14,15).
Despite intensive efforts during the past several years, the
molecular mechanisms by which Treg cells exert their immu-
nosuppressive function still remain undiscovered. A change
in the thyroid microenvironment is believed to follow the
defect in Treg cells. One of the important functions of Treg
cells is to inhibit T helper 1 (Th1)-driven autoimmune and
inflammatory responses (16,17). The defect in Treg cells thus
removes its inhibition on the function of Th1 cells, resulting
in the overproduction of Th1 cytokines, including interleukin
1 beta (IL-1b), interferon gamma (IFNg), and tumor necrosis-
related alpha (TNF). The Th1 cytokine production pattern
occurs not only in intrathyroidal but also in peripheral CD4þ
and CD8þ T lymphocytes in HT patients (18). These cytokines
are able to trigger a number of events, including apoptosis in
thyroid cells (19,20).
Increasing evidence has emerged to support the theory that
the destruction of thyroid follicles occurs by the apoptotic
mechanisms (19,21). Thyroid cells are known to express ap-
optotic ligands and receptors, such as TNF, Fas, and Tumor
necrosis-related apoptosis-inducing ligand (TRAIL) (1). Under
normal physiologic conditions, the apoptotic molecules remain
inactivated or will lack a trigger. Therefore, the thyrocytes are
normally safeguarded against apoptosis through the physio-
logical inhibition of their apoptotic pathways. Though Fas is
known to express constitutively on the thyrocytes, it does not
normally cause apoptosis—even in the presence of excess Fas-
inducing ligands. However, the expression of FasL on thyroid-
infiltrating lymphocytes is usually increased, which leads to
apoptosis of these invading lymphocytes (22). In order to
maintain this finely tuned Fas-FasL pathway, apoptotic sig-
naling would be inhibited in thyrocytes but activated in infil-
trating lymphocytes. The molecules that are responsible for
apoptosis regulation in thyrocytes remain unknown. However,
the inhibition can be reversed by the administration of cyclo-
heximide, an inhibitor of protein translation, suggesting it in-
volves a labile protein (although there may be more than one
inhibitor or labile protein involved) (23). Quite interestingly,
the activation of the Fas-FasL pathway normally inhibited in
thyrocytes is induced by certain combinations of proinflam-
matory cytokines, such as IL-1b, IFNg, and TNF, but not
by any one single cytokine (1,20,21,24). The apoptosis activa-
tion has been associated with an increase of caspases 7, 8, and
10, as well as the concentration of Bid and Bak. A decrease
of p44=42 mitogen-activated protein kinase activity is con-
comitantly observed (19,20,24). Therefore, it appears that
the apoptotic pathway initiated by the Fas-FasL interaction
may be further amplified by the proapoptotic molecule Bid,
leading to the release of Bak from the mitochondria and the
activation of caspases. These observations suggest that
apoptosis of thyrocytes in HT is both a cell death receptor–
dependent and a mitochondrion-dependent event. Un-
fortunately, apoptotic cell clearance does not appear to produce
an anti-inflammatory situation in autoimmune diseases; in-
stead, the impaired apoptotic cells and secondary necrotic cells
induce a proinflammatory state (25), which may provide
sufficient levels of self-antigens to intensify a dysregulated
autoimmune response. Therefore, the apoptosis of thyrocytes
in HT may be both the result of defective immunological tol-
erance and a positive feedback loop to exacerbate thyroid
inflammation.
While defects in the CD4þCD25þ Treg result in the acti-
vation of Th1 cells and the overproduction of Th1 cytokines,
they may also promote an autoimmune response by the
downregulation of a number of molecules that are known to
have immunosuppressive effects. These molecules include
CD25, IL-2, CTLA-4, IL-10, glucocorticoid-induced tumor
necrosis factor receptor (GITR), lymphocyte activation gene-3
(LAG-3), Foxp3, and transforming growth factor-beta (TGFb).
Although none of these molecules can fit into a single model
of immune regulation, it is possible that the reduction of
several of these molecules may enhance the activity of B cells,
which produce autoantibodies, the diagnostic feature of HT
(26,27).
It is not known how the thyroid microenvironment leads to
the defect in CD4þCD25þ Treg cells in the thyroid. The Treg
cells appear to be abundant in inflamed thyroid tissues. How-
ever, they are apparently dysfunctional in most cases and are
unable to downmodulate the autoimmune response (28). The
expression of Fas in CD4þCD25þ Treg cells is greater in pa-
tients with severe HT than in those with mild HT (29). This
phenomenon is consistent with the observation that the pro-
portion of apoptotic cells among CD4þCD25þ Treg cells is
higher than that among CD4þCD25 Treg cells in the thyroid
of a patient with AITD. In addition to the high expression of
Fas in CD4þCD25þ Treg cells in the thyroid, these cells also
strongly express other proapoptotic genes, such as TRAIL and
TNF, and weakly express antiapoptotic genes, such as Bcl-2.
This appears to make the Treg cells uniquely susceptible to
Fas-mediated apoptosis (30,31). Therefore, it has been pro-
posed that the defect or reduction of CD4þCD25þ Treg cells
results from the increased apoptosis of CD4þCD25þ Treg cells
in an inflamed thyroid gland (12). In addition, our recent data
also suggest that TRAIL, a death receptor ligand, can enhance
CD4þCD25þ Treg cell proliferation in vitro (32). This may in-
volve inhibition of the development of experimental autoim-
mune thyroiditis by TRAIL. Further study is underway to
address it.
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Graves’ Disease
GD accounts for most cases of hyperthyroidism. The
identification in the serum of patients with GD of an abnormal
thyroid stimulator protein, originally named long-acting
thyroid stimulator (LATS), that was subsequently identified
as an autoantibody against thyroid follicular cell thyrotropin
(TSH) receptors first identified this disorder as an autoim-
mune disease (5). Similar to HT, GD is characterized by
lymphocytic infiltration of the thyroid gland although much
less severe in nature and not associated with disruption of the
normal thyroid architecture. It is believed that T cells and B
cells accumulate in the thyroid gland as a result of various
factors, such as viral=bacterial infection, stress, sex hormones,
and genetic abnormality. Cytokines and other cellular mole-
cules released during these interactions can upregulate the
expression of major histocompatibility complex (MHC) class I
and class II molecules on the surface of the thyroid cells (33).
These cells may then become adequate antigen-presenting
cells and present a display of TSH receptor peptides. Alter-
natively, infection might produce mimic molecules or alter
host cell components such that they could be attacked by the
immune system (34,35).
An immune response is initiated in GD when T-cell recep-
tors recognize foreign peptides or self-peptide fragments
bound to human leukocyte antigen (HLA) molecules encoded
by MHC genes (33,35). Class II antigens are usually expressed
only on antigen-presenting cells, such as B cells and macro-
phages, and not on epithelial cells, such as thyrocytes. Several
HLA molecules encoded by class II gene region are known to
be associated with GD. Abnormal or aberrant expression of
these antigens on thyrocytes and lymphocytes may play a key
role in the development of GD (33,35).
Analysis of the phenotypic profile of intrathyroidal T
lymphocytes in GD reveals a CD4þ T-cell predominance, but
with some of these T cells expressing CD8 (28). CD4þ T cells
may be capable of helping local B cells to produce antibodies.
Recent studies have indicated that some of the CD4þ T cells in
the thyroids of GD patients are CD4þCD25þ Treg cells (29,36).
The role of the CD4þCD25þ Treg cells in GD is not quite clear.
However, there is evidence that shows that the inhibition of
Treg cells may induce Th2-like cells (37). The cytokines gen-
erated by Th2 cells are IL-4, IL-5, and IL-10, the levels of which
are increased in GD (38,39). Similarly to HT, the number of
Treg cells in GD may also be decreased—probably via the Fas-
mediated apoptotic pathway (36). Therefore, it would appear
that the reduction of Treg cells could favor Th2 cytokine
production in GD.
Th2 cytokine predominance promotes humoral immunity
instead of cellular immunity, enhancing autoantibody pro-
duction by the B lymphocytes. Interestingly, increased con-
centrations of Immunoglobulin G (IgG) due to the activity of
Th2 cells or Th2 cytokines may downregulate the expression
of Fas but upregulate the antiapoptotic molecules, such as
Bcl-2, Bcl-xL, and cFLIP in thyrocytes (2,39–42). This could
lead to the protection of thyrocytes from apoptosis (2,40–43).
In addition, soluble Fas may also play a role in the inhibition
of the Fas-FasL system in patients with GD because the se-
rum concentration of sFas is increased in patients with GD
(44,45). The overexpression of antiapoptosis molecules such
as Bcl-2 may render the thyrocytes of GD resistant to Fas-
FasL–mediated cell death (46). However, this resistance is
not likely to be present in thyroid-infiltrating lymphocytes,
where the expression of proapoptotic Bax and Bak proteins is
apparent (47). Therefore, the infiltrating lymphocytes in GD
thyroids are susceptible to apoptosis, but the thyrocytes may
escape apoptosis via the overexpression of antiapoptotic
molecules (45,46).
Therefore, it appears likely that the thyroid microenvi-
ronment in GD is regulated in a manner that is almost
completely opposite to that of HT (Fig. 1). In GD, the im-
mune response promotes thyrocyte survival and hypertro-
phy and may lead to lymphocyte apoptosis.
Conclusion
Strong evidence has supported the theory that apoptosis
plays an important role in the development of AITD (Fig. 1).
HT and GD are two major forms of AITD. Apoptosis of
thyrocytes is initiated by Th1 cytokines in HT, which over-
come the built-in apoptosis inhibitory mechanisms of the
thyrocytes. In GD, the production of Th2 cytokines dominates
in the thyroid, and thyrocytes are protected from apoptosis
via overexpression of antiapoptotic molecules such as Bcl-2.
The infiltrating lymphocytes appear unable to invoke these
protective mechanisms and thus undergo apoptosis. A defect
in CD4þCD25þ Treg cells is associated with both HT and GD
and is believed to play a critical role in determining the
Alteration of Immune System
CD4+CD25+ T reg
Defective immunological tolerance
Changes in thyroid microenvironment














FIG. 1. Pathogenesis of Hashimoto’s (lymphocytic) thy-
roiditis (HT) and Graves’ disease (GD).
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production of Th1 and Th2 cytokines. It remains unknown
why the defect in CD4þCD25þ Treg cells favors Th1 cytokine
production in HT, whereas it prefers Th2 cytokine production
in GD. This warrants future investigation.
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